FMR1 Gene Screening for Oocyte Donor Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for selecting oocyte donors do not effectively predict premature ovarian aging (POA) or infertility in young females, leading to late diagnosis and limited success in fertility treatments, as they rely on symptoms and are not proactive in identifying genetic risks associated with ovarian health.
Innovation Solution
Performing FMR1 gene tests on oocyte donor candidates to assess their FMR1 genotype, which indicates the likelihood of premature ovarian aging and infertility, allowing for the selection or exclusion of donors based on their genetic profile, thereby predicting and mitigating ovarian aging risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FMR1 gene testing is performed on oocyte donor candidates, then early identification of POA risk is achieved, but testing cost and complexity increase
Solution Approach 1:
The FMR1 gene testing is performed on oocyte donor candidates before they are selected for donation, enabling early identification of those at risk for premature ovarian aging. This preliminary genetic screening allows for proactive exclusion of high-risk candidates before they undergo the donation process, improving the reliability of donor selection while the testing itself is integrated into the existing screening workflow to minimize additional complexity
2Productivity
If FMR1 gene testing is implemented in oocyte donor selection, then fertility treatment success rate is improved, but time and resource consumption increase
Solution Approach 1:
The FMR1 gene test is conducted as part of the initial candidate evaluation process, before final selection for donation. By performing this genetic screening upfront, the method identifies high-risk candidates early, allowing for their exclusion before they commit to the donation process. This preliminary action improves overall treatment success rates by ensuring only low-risk donors are selected, while the integrated timing minimizes additional time loss
3Ease of operation
If current symptom-based methods are used for donor selection, then simplicity of selection process is maintained, but early detection of POA risk is lost
Solution Approach 1:
The FMR1 gene testing is implemented as a preliminary screening step in the donor selection process, performed before final candidate selection. This allows for early detection of POA risk based on genetic markers rather than waiting for symptom manifestation. The testing is integrated into the existing workflow in a way that maintains operational simplicity while dramatically improving detection accuracy through objective genetic data
Data Source
AI summary
Method of selecting oocyte donor candidates for oocyte donation. A number of triple CGG repeats on each allele of the isolated FMR1 gene is measured by using an assay, and an oocyte donor is selected for oocyte donation only if both alleles of the isolated FMR1 gene have more than 26 CGG repeats.